Polyrizon Completes All Five Clinical Sites for NASARIX™ Trial, Moves to Patient Enrollment
PLRZ has more than doubled off its 52-week low of $2.88 on light trading volume (0.2× avg).
Summary
Polyrizon has completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker first-in-human study, up from three sites announced in June. The company is now advancing to patient pre-screening and enrollment, with the 120-patient trial designed to evaluate efficacy, safety, and tolerability in seasonal allergic rhinitis. This marks a key operational milestone toward generating clinical data for a product targeting the U.S. market. Enrollment timing will depend on seasonal allergen exposure, with local pollen counts monitored to optimize recruitment.
At the time of this announcement, PLRZ was trading at $11.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.4M. The 52-week trading range was $2.88 to $18.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.